HBMN:SWX
HBM Healthcare Investments AG
230,00 CHF
0,00%
(0,00) 1D
28. apr., 17:30:57 GMT +2 · CHF
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za HBMN …
Tržna kapitalizacija
1,55 mrd.
Povprečni promet
6,47 tis.
Promet
0,00
Dividenda
3,26 %
Četrtletna dividenda
1,87 CHF
Prvi trgovalni dan brez upravičenja do dividende
2. jul. 2025
Razmerje med ceno delnice in čistim dobičkom
6,40
52-tedenski najvišji tečaj
245,50 CHF
52-tedenski najnižji tečaj
157,40 CHF
Čisti dobiček na delnico
35,93 CHF
Št. izdanih delnic
6,74 mio.
Novice
Iz virov v spletu
Financial Post
·
pred 24 minutami
Nasdaq Futures Rise in Run-Up to Tech Results, Fed: Markets Wrap
Business Wire
·
pred 25 minutami
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
FXStreet
·
pred 58 minutami
S&P 500 Futures (ES) Elliott Wave outlook: Cycle from March 31 low Nearing end [Video]
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Vizitka: HBM Healthcare Investments AG
Generalni direktor-
Št. zaposlenih-
Ustanovljeno12. jul. 2001
SedežZug, Zug, Švica
Sektor-
Spletno mestohbmhealthcare.com
Vsebina z UI lahko vsebuje napake. Več o tem